|
| Status |
Public on Dec 19, 2009 |
| Title |
Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Chronic myelogenous leukemia (CML) is a malignant stem cell disease characterized by a reciprocal translocation between chromosome 9 and 22. The selective bcr-abl tyrosine-kinase inhibitor Imatinib has become the therapy of choice for patients with newly diagnosed CML including those previously considered candidates for allogeneic haematopoietic stem cell transplantation. The tyrosine-kinase inhibitor Nilotinib is a derivate of Imatinib with higher potency.
To examine the molecular and functional effects of Nilotinib and Imatinib in chronic myelogenous leukemia, we performed gene expression and functional analyses in K562 cells following treatment with the two tyrosine kinase inhibitors.
|
| |
|
| Overall design |
Affymetrix U133A 2.0 microarrays were used to examine the gene expression profile of K562 cells after in vitro treatment with Imatinib (0.5 µM) or Nilotinib (0.05 µM) for 24 hours. Gene expression data of the treated cells were compared with data of untreated cells.
|
| |
|
| Contributor(s) |
Bruennert D, Neumann F |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Dec 18, 2009 |
| Last update date |
Dec 06, 2018 |
| Contact name |
Daniela Bruennert |
| E-mail(s) |
Daniela.Bruennert@med.uni-duesseldorf.de
|
| Phone |
0211/8114869
|
| Organization name |
University Clinic Duesseldorf
|
| Department |
Clinic for Hematology, Oncology and clin. Immunology
|
| Lab |
Haematologisches Forschungslabor
|
| Street address |
Universitaetsstr. 1
|
| City |
Duesseldorf |
| ZIP/Postal code |
40225 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL571 |
[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA122473 |
Less...
More...